Type 2 Diabetes Clinical Trials in San Antonio, Texas

14 studies are recruiting for type 2 diabetes in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

   This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join. The study has 3 parts. In each part the study compares survodutide with placebo. Surv…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Pinnacle Clinical Research - San Antonio, San Antonio, Texas

   Locations

   121 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07754461 on ClinicalTrials.gov

2. Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

   CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol. Participants deemed eligible from Part 1 will be randomized to either clofutriben or placebo in th…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Diabetes & Glandular Disease Clinic, P.A., San Antonio, Texas

   Locations

   61 in total

   Run by

   Sparrow Pharmaceuticals

   See if you can join NCT07296484 on ClinicalTrials.gov

3. AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications

   This study is being conducted to find out how well zenagamtide works and how safe it is compared to insulin glargine in participants with type 2 diabetes who are at higher risk of heart and blood vessel problems and are already taking 1 to 3 diabetes medications. There are 2 study treatments in thi…

   Stage

   Phase 3

   Ages

   45 and older

   Site

   Clinical Advancement Center, San Antonio, Texas

   Locations

   330 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07797335 on ClinicalTrials.gov

4. A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

   This clinical study is testing how the study medicine CagriSema helps people living with obesity, with or without type 2 diabetes (T2D), lose weight. The purpose of the study is to find out how safe and effective CagriSema is for body weight loss in these participants. Participants will receive eit…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Quality Research Inc, San Antonio, Texas

   Locations

   303 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07564414 on ClinicalTrials.gov

5. Quantifying Hepatic Mitochondrial Fluxes in Humans

   In this study the investigators will quantitate hepatic mitochondrial fluxes in T2D patients with NAFL and NASH before and after 16-weeks treatment with the insulin sensitizer pioglitazone

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Texas Diabetes Institute - University Health System, San Antonio, Texas

   Locations

   2 in total

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT05305287 on ClinicalTrials.gov

6. SALUD-M: Acceptance Based Coping Skills for Hispanic/Latinx Military Patients With Type 2 Diabetes

   People of Hispanic or Latino/a/x ("H/L") ethnicity, including US military servicemembers, Veterans, and their families, experience a higher prevalence of type 2 diabetes and more challenges managing diabetes than non-Hispanic White populations. Uncontrolled diabetes is linked with lower quality of …

   Stage

   Not phased

   Ages

   18 to 70

   Site

   Brooke Army Medical Center, San Antonio, Texas

   Run by

   Baylor College of Medicine

   See if you can join NCT07674628 on ClinicalTrials.gov

7. SGLTi, Hepatic Glucose Production and Ketogenesis

   In this study, we will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) and type 1 diabetes (T1D), and that the increases in ketone production an…

   Stage

   Phase 1

   Ages

   30 to 75

   Site

   Texas Diabetes Institute/UH, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT05960656 on ClinicalTrials.gov

8. SGLT2i, Hepatic Glucose Production, and SNS

   In this study, PI will test the hypothesis that distinct mechanisms account for the SGLT2i-induced stimulation of ketogenesis and lipolysis versus endogenous (hepatic) glucose production in patients with type 2 diabetes (T2D) that the increases in ketone production and lipolysis can be prevented by…

   Stage

   EARLY_Phase 1

   Ages

   30 to 75

   Site

   Texas Diabetes Institute/UH, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT07053293 on ClinicalTrials.gov

9. SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

   To examine the 2-HIT hypothesis that the SGLT2i-induced stimulation of EGP, lipolysis, and ketone production requires the combination of volume depletion plus insulinopenia in T2D individuals.

   Stage

   Phase 1

   Ages

   30 to 75

   Site

   Texas Diabetes Institute/UH, San Antonio, Texas

   Run by

   The University of Texas Health Science Center at San Antonio

   See if you can join NCT07053306 on ClinicalTrials.gov

10. SGLT2i, Pioglitazone, and Ketone Production in T2D

    To examine whether the empagliflozin-induced stimulation of EGP, lipolysis, and ketone production in T2D individuals can be blocked by pioglitazone (which has direct hepatic and adipose tissue effects).

    Stage

    Phase 1

    Ages

    30 to 75

    Site

    Texas Diabetes Institute/UH, San Antonio, Texas

    Run by

    The University of Texas Health Science Center at San Antonio

    See if you can join NCT07053319 on ClinicalTrials.gov

11. Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

    This is a phase 2 randomized, double-blind, placebo-controlled trial assessing the efficacy and safety of icovamenib in participants with Type 2 Diabetes (T2D) not achieving glycemic targets despite Ozempic-based therapy.

    Stage

    Phase 2

    Ages

    18 to 70

    Site

    Diabetes & Glandular Disease Clinic, P.A., San Antonio, Texas

    Locations

    17 in total

    Run by

    Biomea Fusion Inc.

    See if you can join NCT07502508 on ClinicalTrials.gov

12. HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Diabetes

    Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to ce…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Tekton Research, San Antonio, Texas

    Locations

    25 in total

    Run by

    Housey Healthcare ULC

    See if you can join NCT07546929 on ClinicalTrials.gov

13. Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes

    It is not known whether a new diabetes drug, semaglutide, is an effective treatment for type 2 diabetes for persons with spinal cord injury (SCI), a population at higher risk for this condition. Therefore, this study looks at the effect of semaglutide on glucose levels in the body and other informa…

    Stage

    Phase 4

    Ages

    18 to 70

    Site

    University Health - Texas Diabetic Institute, San Antonio, Texas

    Locations

    2 in total

    Run by

    Marzieh Salehi

    See if you can join NCT06706284 on ClinicalTrials.gov

14. Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes

    This study will provide insight into whether cardiac function changes with oral Ketone Esters (KE) administered to patients with Type 2 Diabetes Mellitus (T2DM) and Heart failure with reduced ejection fraction (HFrEF). Plasma ketones are avidly extracted by cardiac muscle and their uptake is not de…

    Stage

    EARLY_Phase 1

    Ages

    18 to 80

    Site

    University of Texas Health Science Center at San Antonio, San Antonio, Texas

    Run by

    The University of Texas Health Science Center at San Antonio

    See if you can join NCT06108076 on ClinicalTrials.gov